Myriad Genetics, Inc.

668 articles about Myriad Genetics, Inc.

• Myriad Genetics Issues 2022 Environmental, Social and Governance Report

  9/19/2023

  Myriad Genetics, Inc., a leader in genetic testing and precision medicine, released its second annual Environmental, Social and Governance report, highlighting key efforts that reflect its commitment to conduct operations as a responsible, equitable and sustainable partner in the healthcare industry.

• Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials

  9/19/2023

  Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced two key milestones in its strategic partnership with Illumina Inc., a global leader in DNA sequencing and array-based technologies, to advance and support clinical research for gene-based, targeted therapies.

• Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer

  9/18/2023

  Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced a collaboration with Memorial Sloan Kettering Cancer Center to study the use of minimal residual disease testing in breast cancer.

• Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work

  9/6/2023

  Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced Great Place To Work® and Fortune magazine have named Myriad Genetics to the 2023 Fortune Best Workplaces in Health Care™ List.

• Myriad Genetics to Participate in Morgan Stanley Global Healthcare ConferenceMyriad to also host Investor Day in South San Francisco in September 2023

  9/5/2023

  Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced management will participate in the Morgan Stanley 21st Annual Global Healthcare Conference with a fireside chat on Wednesday, Sept. 13, 2023 at 2:15 p.m. EDT.

• Myriad Genetics and Onsite Women’s Health Partner to Help More Women Understand Breast Cancer RiskNew collaboration increases access to genetic testing and can help identify patients with a high-risk for breast cancer

  8/22/2023

  Myriad Genetics, Inc. and Onsite Women’s Health announced the launch of a new breast cancer risk assessment program to help more women understand their breast cancer risk.

• Myriad Genetics to Host Investor Day on September 19, 2023

  8/17/2023

  Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will host an Investor Day at the newly constructed Dr. Walter Gilbert Innovation Center in South San Francisco on September 19, 2023.

• Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®

  8/15/2023

  Myriad Genetics, Inc. , (NASDAQ: MYGN) a leader in genetic testing and precision medicine, today announced the integration of Absolute Risk Reduction (ARR) into the Prolaris ® Prostate Cancer Prognostic Test to help patients and providers make personalized treatment decisions regarding hormone therapy.

• Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer TreatmentComboMATCH study uses genetic testing to match advanced cancer patients with targeted treatments

  8/8/2023

  Myriad Genetics, Inc., a leader in genetic testing and precision medicine, and Intermountain Precision Genomics, part of the Intermountain Health system, will begin providing oncology test results that allow access to the ComboMATCH trials.

• Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status

  8/7/2023

  Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced enhancements to the GeneSight® Psychotropic test, a pharmacogenomic test for mental health medications.

• Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth

  8/3/2023

  Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced financial results for its second quarter ended June 30, 2023.

• Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023

  7/27/2023

  Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its second quarter earnings conference call on Thursday, Aug. 3, 2023 at 4:30 p.m. ET.

• Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment

  7/24/2023

  Myriad Genetics, Inc. today announced its MyRisk ®  Hereditary Cancer Test with RiskScore ®  now incorporates breast density using Tyrer-Cuzick version 8 (TCv8) to provide patients and providers with a more comprehensive look at their five-year and remaining lifetime risk for breast cancer.

• Myriad Genetics Announces New $90 Million Asset-Based Credit Facility

  7/6/2023

  Myriad Genetics, Inc. announced that it has established a new $90 million asset-based credit facility with JPMorgan Chase Bank, N.A. as administrative agent and issuing bank, and the other lender parties thereto consisting of Wells Fargo Bank, N.A. and Bank of America, N.A.

• Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform

  6/12/2023

  Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced an agreement with The University of Texas MD Anderson Cancer Center to support research focused on metastatic renal cell carcinoma treatment selection and response.

• Myriad Genetics to Participate in Goldman Sachs Healthcare Conference

  6/7/2023

  Myriad Genetics, Inc., (NASDAQ: MYGN) today announced Paul J. Diaz, president and CEO, will participate in the 44th Annual Goldman Sachs Global Healthcare Conference with a fireside chat on Tuesday, June 13, 2023 at 2:00 p.m. PT.

• Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023

  6/1/2023

  Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be highlighting new studies and the recent expansion of its Precise™ Oncology Solutions portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6, 2023.

• Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics

  5/31/2023

  Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced it has named Adam Brufsky, MD, PhD, FACP, as Scientific Advisor to its oncology business unit.

• Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer

  5/24/2023

  Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced the addition of Folate Receptor Alpha to its Precise™ Oncology Solutions portfolio.

• Myriad Genetics Earns 2023 Great Place to Work Certification™

  5/8/2023

  Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced it has achieved the Great Place to Work® certification for 2023.